Cannabis in sport: Anti-doping perspective

Sports Medicine

Volumn 41, Issue 11, 2011, Pages 949-966

  Huestis, Marilyn A ^a   Mazzoni, Irene ^b   Rabin, Olivier ^b  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b World Anti Doping Agency (WADA)   (Canada)

Author keywords

Marijuana, abuse; Sports; Sports medicine

Indexed keywords

CANNABINOID; CANNABIS;

COMPETITIVE BEHAVIOR; DOPING; HUMAN; LEGAL ASPECT; REVIEW;

CANNABINOIDS; CANNABIS; COMPETITIVE BEHAVIOR; DOPING IN SPORTS; HUMANS;

EID: 80053938066     PISSN: 01121642     EISSN: 11792035     Source Type: Journal    
DOI: 10.2165/11591430-000000000-00000     Document Type: Review

References (135)

1. International Olympic Committee. Prohibited classes of substances and prohibited methods. Olympic Movement Anti-Doping Code: appendix A. Lausanne: International Olympic Committee, 2003
2. World Anti-Doping Agency (WADA). The 2004 prohibited list. Montreal (QC): WADA, 2004
3. World Anti-Doping Agency (WADA). World anti-doping code. Montreal (QC): WADA, 2009: 29
4. World Anti-Doping Agency (WADA). World anti-doping code. Montreal (QC): WADA, 2003: 14
5. Turner CE, Elsohly MA, Boeren EG. Constituents of Cannabis sativa L: XVII. A review of the natural constituents. J Nat Prod 1980; 43: 169-234 (Pubitemid 10020139)
6. Musty RE, Conti LH, Mechoulam R. Anxiolytic properties of cannabidiol. In: Harvey DJ, editor. Marihuana '84: proceedings of the Oxford Symposium on Cannabis. Oxford: IRL Press Ltd, 1994: 713-9
7. Onaivi ES, Green MR, Martin BR. Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 1990; 253: 1002-9 (Pubitemid 20209356)
8. Zuardi AW, Crippa JAS, Hallak JEC, et al. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006; 39: 421-9
9. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005; 172: 1703-11 (Pubitemid 40896865)
10. Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004; 10 (4): 434-41 (Pubitemid 39117341)
11. Riedel G, Davies SN. Cannabinoid function in learning, memory and plasticity. In: Pertwee RG, editor. Handbook of experimental pharmacology, Vol. 168. New York (NY): Springer, 2005: 446-70
12. Ramaekers JG, Berghaus G, van Laar M, et al. Doserelated risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend 2004; 73: 109-19 (Pubitemid 38068347)
13. Verdejo-Garcia A, Benbrook A, Funderburk F, et al. The differential relationship between cocaine use and marijuana use on decision-making performance over repeat testing with the Iowa Gambling Task. Drug Alcohol Depend 2007; 90 (1): 2-11 (Pubitemid 46935369)
14. Blair RE, Deshpande LS, Sombati S, et al. Prolonged exposure to WIN55,212-2 causes downregulation of the CB1 receptor and the development of tolerance to its anticonvulsant effects in the hippocampal neuronal culture model of acquired epilepsy. Neuropharmacology 2009; 57: 208-18
15. Cabral GA, Griffin-Thomas L. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med 2009 Jan 20; 11: e3
16. Fattore L, Fadda P, Spano MS, et al. Neurobiological mechanisms of cannabinoid addiction. Mol Cell Endocrinol 2008; 286 (1-2 Suppl. 1): S97-107
17. Huestis MA, Smith ML. Human cannabinoid pharmacokinetics and interpretation of cannabinoid concentrations in biological fluids and tissues. In: ElSohly MA, editor. Marijuana and the cannabinoids. Totowa (NJ): Humana Press, 2006: 205-36
18. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). A cannabis reader: global issues and local experiences. Monograph, series 8, Volume 2. Lisbon: EMCDDA, 2008
19. National Drug Strategy. Cannabis in Australia: use, supply and responses. Monograph Series no. 57. Canberra (ACT): Australian Government, Department of Health and Ageing, 2006
20. National Drug Strategy. Cannabis and mental health: put into context. Monograph Series no. 68. Canberra (ACT): Australian Government, Department of Health and Ageing, 2008
21. Moreira FA, Lutz B. The endocannabinoid system: emotion, learning and addiction. Addict Biol 2008; 13: 196-212 (Pubitemid 351698889)
22. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids: I. Absorption of THC and formation of 11-OHTHC and THCCOOH during and after smoking marijuana. J Anal Toxicol 1992; 16: 276-82
23. Huestis MA, Sampson A, Holicky B, et al. Characterization of the absorption phase of marijuana smoking. Clin Pharmacol Ther 1992; 52: 31-41
24. Gorelick DA, Heishman SJ, Preston KL, et al. The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. Am Heart J 2006; 151: 754.e1-5
25. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug abuse warning network, 2006: national estimates of drug-related emergency department visits. DAWN Series D-30. Rockville (MD): US Department of Health and Human Services, 2008. DHHS publication no.: (SMA) 08-4339
26. Appelboam A, Oades PJ. Coma due to cannabis toxicity in an infant. Eur J Emerg Med 2006; 13: 177-9 (Pubitemid 44153108)
27. Robinson K. Beyond resinable doubt? J Clin Forensic Med 2005; 12: 164-6 (Pubitemid 40704379)
28. Richer I, Bergeron J.Driving under the influence of cannabis: links with dangerous driving, psychological predictors, and accident involvement. Accid Anal Prev 2009; 41: 299-307
29. Hunt CA, Jones RT. Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther 1980; 215: 35-44
30. Bolla KI, Brown K, Eldreth D, et al. Dose-related neurocognitive effects of marijuana use. Neurology 2002; 59: 1337-43 (Pubitemid 35285983)
31. Pope Jr HG, Gruber AJ, Hudson JI, et al. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001; 58: 909-15 (Pubitemid 32937912)
32. Karschner EL, Schwilke EW, Lowe RH, et al. Do delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Addiction 2009; 104: 2041-8
33. Karschner EL, Schwilke EW, Lowe RH, et al. Implications of plasma delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers. J Anal Toxicol 2009; 33: 469-77
34. Lowe RH, Abraham TT, Darwin WD, et al. Extended urinary delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend 2009; 105: 24-32
35. Hall W, Degenhardt L. Adverse health effects of nonmedical cannabis use. Lancet 2009; 374: 1383-91
36. Singh R, Sandhu J, Kaur B, et al. Evaluation of the DNA damaging potential of cannabis cigarette smoke by the determination of acetaldehyde derived N2-ethyl-2'-deoxyguanosine adducts. Chem Res Toxicol 2009; 22: 1181-8
37. Moir D, Rickert WS, Levasseur G, et al. A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions. Chem Res Toxicol 2008; 21: 494-502
38. Bailey JR, Cunny HC, Paule MG, et al. Fetal disposition of delta 9-tetrahydrocannabinol (THC) during late pregnancy in the rhesus monkey. Toxicol Appl Pharmacol 1987; 90: 315-21 (Pubitemid 18009154)
39. Battista N, Bari M, Rapino C, et al. Regulation of female fertility by the endocannabinoid system. Hum Fertil (Camb) 2007; 10: 207-16 (Pubitemid 350215067)
40. Campolongo P, Trezza V, Palmery M, et al. Developmental exposure to cannabinoids causes subtle and enduring neurofunctional alterations. Int Rev Neurobiol 2009; 85: 117-33
41. Porath AJ, Fried PA. Effects of prenatal cigarette and marijuana exposure on drug use among offspring. Neurotoxicol Teratol 2005; 27: 267-77 (Pubitemid 40282590)
42. Cabral GA. Drugs of abuse, immune modulation, and AIDS. J Neuroimmune Pharmacol 2006; 1: 280-95 (Pubitemid 44244133)
43. Croxford JL, Yamamura T. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J Neuroimmunol 2005; 166: 3-18 (Pubitemid 41074652)
44. Ottani A, Giuliani D. HU-210: a potent tool for investigations of the cannabinoid system. CNS Drug Rev 2001; 7: 131-45 (Pubitemid 32656298)
45. Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009; 156: 397-411
46. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77 (2): 299-318 (Pubitemid 27079604)
47. Drummer OH, Gerostamoulos J, Batziris H, et al. The incidence of drugs in drivers killed in Australian road traffic crashes. Forensic Sci Int 2003; 134: 154-62 (Pubitemid 36808942)
48. Janowsky DS, Meacham MP, Blaine JD, et al. Simulated flying performance after marihuana intoxication. Aviat Space Environ Med 1976; 47: 124-8
49. Yesavage JA, Leirer VO, Denari M, et al. Carry-over effects of marijuana intoxication on aircraft pilot performance: a preliminary report. Am J Psychiatry 1985; 142: 1325-9 (Pubitemid 16216571)
50. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Synthetic cannabinoids and 'Spice'. 2009 [online]. Available from URL: http://www.emcdda. europa.eu/publications/drug-profiles/synthetic-cannabino ids [Accessed 2011 Aug 31]
51. Skinner R, Conlon L, Gibbons D, et al. Cannabis use and non-clinical dimensions of psychosis in university students presenting to primary care. Acta Psychiatr Scand 2011; 123: 21-7
52. Scholes KE, Martin-Iverson MT. Alterations to pre-pulse inhibition (PPI) in chronic cannabis users are secondary to sustained attention deficits. Psychopharmacology (Berl) 2009; 207: 469-84
53. Hunault CC, Mensinga TT, Bö cker KB, et al. Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC). Psychopharmacology (Berl) 2009; 204: 85-94
54. Solowij N. Do cognitive impairments recover following cessation of cannabis use? Life Sci 1995; 56: 2119-26
55. Pope Jr HG, Gruber AJ, Hudson JI, et al. Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend 2003; 69: 303-10 (Pubitemid 36293942)
56. McHale S, Hunt N. Executive function deficits in shortterm abstinent cannabis users. Hum Psychopharmacol 2008; 23: 409-15
57. LynskeyM, Hall W. The effects of adolescent cannabis use on educational attainment: a review. Addiction 2000; 95: 1621-30
58. Tashkin DP. Smoked marijuana as a cause of lung injury. Monaldi Arch Chest Dis 2005; 63: 93-100 (Pubitemid 41167514)
59. Reece AS. Chronic toxicology of cannabis. Clin Toxicol (Phila) 2009; 47: 517-24
60. Purohit V, Rapaka R, Shurtleff D. Role of cannabinoids in the development of fatty liver (steatosis). AAPS J 2010; 12: 233-7
61. Whan LB, West MC, McClure N, et al. Effects of delta-9- tetrahydrocannabinol, the primary psychoactive cannabinoid in marijuana, on human sperm function in vitro. Fertil Steril 2006; 85: 653-60 (Pubitemid 43261558)
62. Welch KA, McIntosh AM, Job DE, et al. The impact of substance use on brain structure in people at high risk of developing schizophrenia. Schizophr Bull. Epub 2010 Mar 11
63. Mazzoncini R, Donoghue K, Hart J, et al. Illicit substance use and its correlates in first episode psychosis. Acta Psychiatr Scand. Epub 2009 Oct 13
64. Vandrey R, Haney M. Pharmacotherapy for cannabis dependence: how close are we? CNS Drugs 2009; 23 (7): 543-53
65. Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Curr Opin Psychiatry 2006; 19: 233-8 (Pubitemid 44309479)
66. Vandrey R, Budney AJ, Kamon JL, et al. Cannabis withdrawal in adolescent treatment seekers. Drug Alcohol Depend 2005; 78: 205-10 (Pubitemid 40544608)
67. Copersino ML, Boyd SJ, Tashkin DP, et al. Cannabis withdrawal among non-treatment-seeking adult cannabis users. Am J Addict 2006; 15: 8-14 (Pubitemid 43207184)
68. Hasin DS, Keyes KM, Alderson D, et al. Cannabis withdrawal in theUnited States: results from NESARC. J Clin Psychiatry 2008; 69: 1354-63
69. Cornelius JR, Chung T, Martin C, et al. Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence. Addict Behav 2008; 33: 1500-5
70. Lupica CR, Riegel AC, Hoffman AF. Marijuana and cannabinoid regulation of brain reward circuits. Br J Pharmacol 2004; 143: 227-34 (Pubitemid 39315142)
71. Gardner EL. Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol BiochemBehav 2005; 81: 263-84 (Pubitemid 40807127)
72. Zangen A, Solinas M, Ikemoto S, et al. Two brain sites for cannabinoid reward. J Neurosci 2006; 26: 4901-7 (Pubitemid 44315331)
73. Solinas M, Yasar S, Goldberg SR. Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacol Res 2007; 56: 393-405 (Pubitemid 350030891)
74. Matthew RJ,Wilson WH, Turkington TG, et al. Cerebellar activity and disturbed time sense after THC. Brain Res 1998; 797: 183-9 (Pubitemid 28332730)
75. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001; 178: 101-6 (Pubitemid 32158071)
76. Wachtel SR, ElSohly MA, Ross SA, et al. Comparison of the subjective effects of delta(9)-tetrahydrocannabinol and marijuana in humans. Psychopharmacology (Berl) 2002; 161: 331-9
77. Grotenhermen F. The toxicology of cannabis and cannabis prohibition. Chem Biodivers 2007; 4: 1744-69
78. Steadward RD, SinghM. The effects of smokingmarihuana on physical performance. Med Sci Sports 1975; 7: 309-11
79. Renaud AM, Cormier Y. Acute effects of marihuana smoking on maximal exercise performance. Med Sci Sports Exerc 1986; 18: 685-9 (Pubitemid 17216359)
80. Berrendero F, Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl) 2002; 163: 111-7 (Pubitemid 34985320)
81. SaugyM, Avois L, Saudan C, et al. Cannabis and sport. Br J Sports Med 2006; 40 Suppl. 1: i13-5 (Pubitemid 44032624)
82. Bortolato M, Campolongo P, Mangieri RA, et al. Anxiolytic-like properties of the anadamide transport inhibitor AM404. Neuropsychopharmacology 2006; 31: 2652-9 (Pubitemid 44764162)
83. Naidu PS, Varel SA, Ahn K, et al. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) 2007; 192: 61-70 (Pubitemid 46673891)
84. Moreira FA, Aguiar DC, Guimaraes FS. Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1466-71 (Pubitemid 44634958)
85. Haller J, Varga B, Ledent C, et al. Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur J Neurosci 2004; 19: 1906-12 (Pubitemid 38482578)
86. McDonald J, Schleifer L, Richards JB, et al. Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology 2003; 28: 1356-65 (Pubitemid 41070907)
87. Lane SD, Cherek DR, Tcheremissine OV, et al. Acute marijuana effects on human risk taking. Neuropsychopharmacology 2005; 30: 800-9 (Pubitemid 40397087)
88. Martinez D. Le dopage au cannabis releve surtout de la question des droits et des devoirs du sportif. 20 Minutes France, 2007 Jan 31 [online]. Available from URL: http://www.20minutes.fr/article/136277/Sport-Le-dopage-au- can nabis-releve-surtout-de-la-question-des-droits-et-des-devoirsdu-sportif.php [Accessed 2011 Aug 31]
89. Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418: 530-4 (Pubitemid 34851398)
90. Chhatwal JP, Davies M, Maguschak KA, et al. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 2005; 30: 516-24 (Pubitemid 40271154)
91. Lutz B. The endocannabinoid system and extinction learning. Mol Neurobiol 2007; 36: 92-101 (Pubitemid 351360355)
92. Wagner JC. Abuse of drugs used to enhance athletic performance. Am J Hosp Pharm 1989; 46: 2059-67 (Pubitemid 20013964)
93. Bambico FR, Katz N, Debonnel G, et al. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci 2007; 27: 11700-11 (Pubitemid 350006914)
94. Bortolato M, Mangieri RA, Fu J, et al. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 2007; 62: 1103-10 (Pubitemid 350029716)
95. Chabrol H, Ducongé E, Casas C, et al. Relations between cannabis use and dependence, motives for cannabis use and anxious, depressive and borderline symptomatology. Addict Behav 2005; 30: 829-40 (Pubitemid 40516847)
96. Simons JS, Gaher RM, Correia CJ, et al. An affectivemotivational model of marijuana and alcohol problems among college students. Psychol Addict Behav 2005; 19: 326-34 (Pubitemid 41429164)
97. Bonn-Miller MO, Zvolensky MJ, Bernstein A. Marijuana use motives: concurrent relations to frequency of past 30-day use and anxiety sensitivity among young adult marijuana smokers. Addict Behav 2007; 32: 49-62 (Pubitemid 44708486)
98. Catlin DH, Murray TH. Performance-enhancing drugs, fair competition, and Olympic sport. JAMA 1996; 276: 231-7 (Pubitemid 26235069)
99. Iven VG. Recreational drugs. Clin Sports Med 1998; 17 (2): 245-59 (Pubitemid 28193808)
100. Lorente FO, Peretti-Watel P, Grelot L. Cannabis use to enhance sportive and non-sportive performances among French sport students. Addict Behav 2005; 30: 1382-91 (Pubitemid 40973793)
101. Pillard F, Cances-Lauwers V, Godeau E, et al. Sport practice and cannabis consumption in a representative sample of French high school adolescents [in French]. Ann Med Interne (Paris) 2001; 152 Suppl. 7: 28-36
102. Red C, Quinn TJ, O'Keeffe M. Reefer madness: why more athletes are turning to marijuana. New York Daily News 2003 May 4 [online]. Available from URL: http://articles. nydailynews.com/2003-05-04/sports/18221489-1-wadatesting- marijuana [Accessed 2011 Sep 7]
103. USA Swimming. Updated statement from USA Swimming regarding Michael Phelps. 2009 February 5 [online]. Available from URL: http://www.usaswimming. org/USASWeb/ViewNewsArticle.aspx?TabId=0&Alias=Rain bow&Lang= en&ItemId=2354&mid=2943 [Accessed 2011 Aug 31]
104. Van Valkenburg K. Michael Phelps suspended 3 months. Baltimore Sun 2009 Feb 6 [online]. Available from URL: http://www.baltimoresun.com/sports/olympics/ bal-sp.ph elps06feb06,0,1898488.story [Accessed 2011 Aug 31]
105. World Anti-Doping Agency (WADA). WADA technical document: Decision limits for the confirmatory quantification TD2011DL. The world anti-doping code. International Standards for Laboratories [online]. Available from URL: http://www.wada-ama.org/Documents/World-Anti-Doping-Program/WADP-IS- Laboratories/WADA-TD2 010DLv1.0-Decision%20Limits%20for%20the%20Conf irmatory%20Quantification%20of%20Threshold%20Sub stances-May%2008%202010-EN.doc. pdf [Accessed 2011 Sep 5]
106. Goodwin RS, Gustafson RA, Barnes A, et al. Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)- tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids. Ther Drug Monit 2006; 28: 545-51 (Pubitemid 44181489)
107. Huestis MA, Mitchell JM, Cone EJ. Urinary excretion profiles of 11-nor-9-carboxy-delta 9-tetrahydrocannabinol in humans after single smoked doses of marijuana. J Anal Toxicol 1996; 20: 441-52 (Pubitemid 26327467)
108. McGilveray IJ. Pharmacokinetics of cannabinoids. Pain Res Manag 2005; 10 Suppl. A: 15A-22A (Pubitemid 44796349)
109. Hunault CC, Mensinga TT, de Vries I, et al. Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69mg THC. Psychopharmacology (Berl) 2008; 201: 171-81
110. Huestis MA, Cone EJ. Urinary excretion half-life of 11-Nor-9-carboxy- delta9-tetrahydrocannabinol in humans. Ther Drug Monit 1998; 20: 570-6 (Pubitemid 28463451)
111. Huestis MA, Mitchell JM, Cone EJ. Detection times of marijuana metabolites in urine by immunoassay and GCMS. J Anal Toxicol 1995; 19: 443-9
112. Niedbala RS, Kardos KW, Fritch DF, et al. Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana. J Anal Toxicol 2001; 25: 289-303 (Pubitemid 32656280)
113. Goodwin RS, Darwin WD, Chiang CN, et al. Urinary elimination of 11-nor-9-carboxy-delta9-tetrahydrocannnabinol in cannabis users during continuously monitored abstinence. J Anal Toxicol 2008; 32: 562-9
114. Smith ML, Barnes AJ, Huestis MA. Identifying new cannabis use with urine creatinine-normalized THCCOOH concentrations and time intervals between specimen collections. J Anal Toxicol 2009; 33: 185-9
115. Schwilke EW, Gullberg RG, Darwin WD, et al. Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users. Addiction 2011; 106: 499-506
116. Kemp PM, Abukhalaf IK, Manno JE, et al. Cannabinoids in humans: II. The influence of three methods of hydrolysis on the concentration of THC and two metabolites in urine. J Anal Toxicol 1995; 19: 292-8
117. Manno JE, Manno BR, Kemp PM, et al. Temporal indication of marijuana use can be estimated from plasma and urine concentrations of delta9- tetrahydrocannabinol, 11-hydroxy-delta9-tetrahydrocannab-inol, and 11-nordelta9-tetrahydrocannabinol-9-carboxylic acid. J Anal Toxicol 2001; 25: 538-49 (Pubitemid 32939055)
118. ElSohly MA, deWit H, Wachtel SR, et al. Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study. J Anal Toxicol 2001; 25: 565-71 (Pubitemid 32939059)
119. Levin FR, Mariani JJ, Brooks DJ, et al. Delta9-tetrahydrocannabivarin testing may not have the sensitivity to detect marijuana use among individuals ingesting dronabinol. Drug Alcohol Depend 2010; 106: 65-8
120. Jung J, Kempf J, Mahler H, et al. Detection of delta9- tetrahydrocannabinolic acid A in human urine and blood serum by LC-MS/MS. J Mass Spectrom 2007; 42: 354-60 (Pubitemid 46426679)
121. Jung J, Meyer MR, Maurer HH, et al. Studies on the metabolism of the delta9-tetrahydrocannabinol precursor delta9-tetrahydrocannabinolic acid A (delta9-THCA-A) in rat using LC-MS/MS, LC-QTOF MS and GC-MS techniques. J Mass Spectrom 2009; 44: 1423-33
122. World Anti-Doping Agency. International Standard for Laboratories. 2009 [online]. Available from URL: http://www.wada-ama.org/en/Science-Medicine/Anti- Doping-Laboratories/International-Standard-for-Laboratories/[Accessed 2011 Sep 7]
123. Mulé SJ, Lomax P, Gross SJ. Active and realistic passive marijuana exposure tested by three imunoassays and GC/MS in urine. J Anal Toxicol 1988; 12: 113-6
124. Westin AA, Slørdal L. Passive inhalation of cannabis smoke: is it detectable [in Norwegian]? Tidsskr Nor Laegeforen 2009; 129: 109-13
125. Cone EJ. Marijuana effects and urinalysis after passive inhalation and oral ingestion. NIDA Res Monogr 1990; 99: 88-96
126. Cone EJ, Johnson RE. Contact highs and urinary cannabinoid excretion after passive exposure to marijuana smoke. Clin Pharmacol Ther 1986; 40: 247-56 (Pubitemid 16017849)
127. Cone EJ, Johnson RE, Darwin WD, et al. Passive inhalation of marijuana smoke: urinalysis and room air levels of delta-9-tetrahydrocannabinol. J Anal Toxicol 1987; 11: 89-96 (Pubitemid 17077484)
128. Law B, Mason PA, Moffat AC, et al. Passive inhalation of cannabis smoke. J Pharm Pharmacol 1984; 36: 578-81 (Pubitemid 14068718)
129. Morland J, Bugge A, Skuterud B, et al. Cannabinoids in blood and urine after passive inhalation of cannabis smoke. J Forensic Sci 1985; 30: 997-1002 (Pubitemid 16253465)
130. Perez-Reyes M, Di Guiseppi S, Mason AP, et al. Passive inhalation of marijuana smoke and urinary excretion of cannabinoids. Clin Pharmacol Ther 1983; 34: 36-41 (Pubitemid 13073299)
131. El Sohly MA. Practical challenges to positive drug tests for marijuana. Clin Chem 2003; 49: 1037-8
132. Pijlman FT, Rigter SM, Hoek J, et al. Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addict Biol 2005; 10: 171-80 (Pubitemid 40976387)
133. Office of National Drug Control Policy. 2001 National Household Survey on Drug Abuse (NHSDA) [online]. Available from URL: http://oas.samhsa.gov/nhsda/ 2k1nhsda/PDF/cover.pdf [Accessed 2011 Sep 7]
134. European School Survey Project on Alcohol and Other Drugs (ESPAD). Alcohol and drug use among European 17-18 year old students: data from the ESPAD Project. 2007 [online]. Available from URL: http://www.espad. org/documents/Espad/ESPAD-reports/ESPAD-17-18-Year-Old-2003.pdf [Accessed 2011 Sep 5]
135. US Department of Health and Human Services. Substance Abuse and Mental Health Services Administration (SAMHSA): 2006 National Survey on Drug Use and Health [online]. Available from URL: http://oas.samhsa. gov/nsduh/2k6nsduh/ 2k6results.cfm [Accessed 2011 Aug 31]